Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00343616
Registration number
NCT00343616
Ethics application status
Date submitted
22/06/2006
Date registered
23/06/2006
Date last updated
27/07/2012
Titles & IDs
Public title
Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98
Query!
Scientific title
Investigating Cognitive Function for Patients Participating in the BIG Trial 1-98 in Select Centers
Query!
Secondary ID [1]
0
0
IBCSG-18-98-CFS
Query!
Secondary ID [2]
0
0
CDR0000482396
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Cognitive/Functional Effects
0
0
Query!
Fatigue
0
0
Query!
Psychosocial Effects of Cancer and Its Treatment
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Surgery - cognitive assessment
Treatment: Surgery - fatigue assessment and management
Treatment: Surgery - psychologic distress
Treatment: Surgery - quality-of-life assessment
Experimental: Tamoxifen for 5 years - Patients treated with tamoxifen for 5 years after randomization.
Experimental: Letrozole for 5 years - Patients treated with letrozole for 5 years after randomization.
Experimental: Tamoxifen 2 years plus letrozole 3 years - Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
Experimental: Letrozole for 2 years plus tamoxifen for 3 years - Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
Treatment: Surgery: cognitive assessment
Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
Treatment: Surgery: fatigue assessment and management
Fatigue will be evaluated using the Brief Fatigue Inventory.
Treatment: Surgery: psychologic distress
Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
Treatment: Surgery: quality-of-life assessment
Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
Query!
Intervention code [1]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective cognitive function as measured by the CogState battery
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
6 years after randomization
Query!
Secondary outcome [1]
0
0
Subjective cognitive function as measured by the Cognitive Failures Questionnaire (CFQ)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
6 years after randomization
Query!
Secondary outcome [2]
0
0
Psychological distress as measured by the General Health Questionnaire (GHQ)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
6 years after randomization
Query!
Secondary outcome [3]
0
0
Fatigue as measured by the Brief Fatigue Inventory (BFI)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
6 years after randomization
Query!
Secondary outcome [4]
0
0
Quality of life as measured by the IBCSG QL Core Form
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
6 years after randomization
Query!
Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:
- Enrolled in protocol IBCSG-1-98
- Must be in the fifth year of study treatment (i.e., still receiving tamoxifen or
letrozole)
- No breast cancer recurrence or second malignancy
- Patients who received 2-4½ years of tamoxifen and have chosen to switch to letrozole
to complete 5 years of treatment on protocol IBCSG-1-98 are not eligible
- Hormone receptor status
- Estrogen receptor- and/or progesterone receptor-positive tumor
PATIENT CHARACTERISTICS:
- Female
- Postmenopausal
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent hormone replacement therapy
Query!
Minimum age
30
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
135
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Institute of Oncology at Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [2]
0
0
Peter MacCallum Cancer Centre - East Melbourne
Query!
Recruitment hospital [3]
0
0
St. Vincent's Hospital - Melbourne - Fitzroy
Query!
Recruitment hospital [4]
0
0
Cabrini Hospital - Malvern
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [3]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [4]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Brussels
Query!
Country [2]
0
0
Italy
Query!
State/province [2]
0
0
Milan
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Auckland
Query!
Country [4]
0
0
Switzerland
Query!
State/province [4]
0
0
Basel
Query!
Country [5]
0
0
Switzerland
Query!
State/province [5]
0
0
Bellinzona
Query!
Country [6]
0
0
Switzerland
Query!
State/province [6]
0
0
Bern
Query!
Country [7]
0
0
Switzerland
Query!
State/province [7]
0
0
St. Gallen
Query!
Country [8]
0
0
United Kingdom
Query!
State/province [8]
0
0
Scotland
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
ETOP IBCSG Partners Foundation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE: Studying cognitive function, such as thinking, attention, concentration, and
memory, in postmenopausal women receiving hormone therapy for breast cancer may help improve
quality of life and the ability to plan treatment for cancer.
PURPOSE: This phase III trial is studying cognitive function in postmenopausal women with
breast cancer receiving hormone therapy on clinical trial IBCSG-1-98.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00343616
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Kelly-Anne Phillips
Query!
Address
0
0
Peter MacCallum Cancer Centre, Australia
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00343616
Download to PDF